Aronora Inc.

Bayer AG has confirmed that of the three projects in its Factor XIa program, the full focus is now on the oral treatment asundexian, ahead of two partnered therapies – fesomersen and osocimab – which

Bayer AG has posted a strong set of financials for the first quarter and while its pharmaceuticals division's sales slightly missed analyst forecasts, the German major is pleased with the performance

Bayer AG has posted a healthy set of financials for the fourth quarter with its pharmaceuticals division continuing to recover from the effects of COVID 19 and make progress with the pipeline, notabl

Bayer AG s expansion into new drug modalities has caught the eye, not least the launch of a dedicated cell and gene therapy unit, but the German major needs its recent launches to succeed and the late